Here is What Hedge Funds Think About Sanofi SA (ADR) (SNY)

Judging by the fact that Sanofi SA (ADR) (NYSE:SNY) has experienced a weakening in popularity among hedge fund managers, we can see that there were a few funds who were dropping their full holdings heading into Q4. It’s worth mentioning that Clifford Fox’s Columbus Circle Investors said goodbye to the largest stake of the 700 funds followed by Insider Monkey, comprising an estimated $25.4 million in stock. Michael Messner’s fund, Seminole Capital (Investment Mgmt), also dumped its holding, about $16.3 million worth. On the other hand, Peter Rathjens, Bruce Clarke, and John Campbell’s Arrowstreet Capital and Michael Castor’s Sio Capital initiated the largest stakes in the third quarter, valued at around $9.8 million and $6.2 million, respectively.

Let’s go over hedge fund activity in other stocks similar to Sanofi SA (ADR) (NYSE:SNY). These stocks are Philip Morris International Inc. (NYSE:PM), Unilever N.V. (ADR) (NYSE:UN), Unilever plc (ADR) (NYSE:UL), and UnitedHealth Group Inc. (NYSE:UNH). This group of stocks’ market valuations match SNY’s market valuation.

As you can see, these stocks had an average of 30 hedge funds with bullish positions and the average amount invested in these stocks was $1.82 billion. In Sanofi, hedge funds have amassed stakes with a total value of $971 million. UnitedHealth Group Inc. (NYSE:UNH) is the most popular stock in this table with 51 long positions, while Unilever N.V. (ADR) (NYSE:UN) is the least popular one. Sanofi SA (ADR) (NYSE:SNY) is not the most popular stock in this group but hedge fund interest is still above average. With this in mind, we think that Sanofi may be a good investment, but a more detailed analysis is required to assess the performance of the company.